The in vitro activities of magainin II, nisin, and ranalexin alone and in combination with other antimicrobial agents against six clinical isolates of Rhodococcus equi were investigated by MIC and time-kill studies. All isolates were more susceptible to nisin. A positive interaction was observed when the peptides were combined with ampicillin, ceftriaxone, rifabutin, rifampin, azithromycin, clarithromycin, and vancomycin.
by inserting into the cytoplasmic membrane and triggering the activity of bacterial murein hydrolases, resulting in damage or degradation of the peptidoglycan and lysis of the cell (4, 9, 11, 12) .
The magainins and ranalexin are polycationic peptides that have been isolated from amphibian skin. Magainin II is a small peptide (23 residues) present in the skin of Xenopus laevis, while ranalexin is a 20-amino-acid peptide that was recently isolated from the skin of the American bullfrog (Rana catesbiana) (3, 19) . Magainins and ranalexin appear to be responsible for the extraordinary freedom from infection characteristic of wound healing in laboratory animals, despite the use of nonsterile surgical procedures. Magainins form an amphipathic helical structure; this geometry is considered the key factor for the formation of transmembrane pores, which leads to cell death (19) . Ranalexin shares remarkable structural similarity with the polymyxins, a class of membrane-active antibiotics (6, 16, 18) . Nisin is a cationic peptide produced by Streptococcus lactis subsp. lactis; it has activity against a wide range of gram-positive bacteria including several important, contemporary multidrug-resistant gram-positive pathogens (14) . In this study we investigated the in vitro activities of magainin II, nisin, and ranalexin against R. equi.
Six distinct clinical isolates of R. equi were tested. They were isolated over a 10-year period from distinct patients with unrelated sources of infection. When a strain was repeatedly isolated from the same individual, only the first isolate was tested. The strains were identified according to the following characteristics or criteria: gram-positive, coccobacillary, nonspore-forming, nonmotile organisms; weak or partial acid fastness; mucoid colonies; salmon pink-or coral-colored colonies; inability to ferment carbohydrates; inability to hydrolyze casein, hypoxanthine, xanthine, tyrosine, and gelatin; catalase positivity; urease positivity; oxidase negativity; nitrate reduction positivity; and alkaline phosphatase positivity (1).
FIG. 1. Time-kill kinetics of nisin (a), ranalexin (b), and magainin II (c) against six strains of R. equi. The peptides were each tested at a concentration of 32 g/ml. }, strain 1; s, strain 2; OE, strain 3; ϫ, strain 4; E, strain 5; F, strain 6.
Magainin II, nisin, and ranalexin were obtained from Sigma-Aldrich (Milan, Italy). They were solubilized in phosphatebuffered saline (pH 7.2), yielding a stock solution of 1,000 mg/liter. Other agents evaluated were ampicillin, ceftriaxone, doxycycline, netilmicin, ofloxacin, rifampin, and vancomycin (all from Sigma-Aldrich), azithromycin (Pfizer/Roerig, Rome, Italy), clarithromycin (Abbott, Rome, Italy), and rifabutin (Pharmacia & Upjohn, Milan, Italy). Laboratory standard powders were diluted in accordance with the manufacturer's recommendations, yielding a stock solution of 1 mg/ml. The stock solutions of these antimicrobial drugs were stored at Ϫ80°C until they were used. Each antibiotic was assayed over a concentration range of 0.06 to 256 g/ml.
The MIC was determined in triplicate by a microbroth dilution method with Mueller-Hinton (MH) broth (Becton Dickinson Italia, Milan, Italy) and an initial inoculum of 5 ϫ 10 5 CFU/ml. Ninety-six well polystyrene plates (Becton Dickinson and Co., Franklin Lakes, N.J.) were incubated for 18 h at 37°C in air. Since the peptides have a tendency to precipitate, the plates were shaken throughout the study. The MIC was the lowest drug concentration at which observable growth was inhibited.
To study the in vitro killing effects of the peptides, the six isolates were grown at 37°C in MH broth. Aliquots of exponentially growing bacteria were resuspended in fresh MH broth at approximately 10 7 cells/ml and were exposed to each peptide (final concentration, 32 g/ml) for 0, 10, 20, 30, 40, 50, and 60 min at 37°C. After these times the samples (0.1 ml) were serially diluted by preparing consecutive 1:10 (vol/vol) dilutions in MH broth, and the dilutions were plated onto MH agar plates to obtain viable colonies. The experiments were performed in triplicate. Antibiotic carryover was not a problem in these experiments (8, 13) , although preliminary studies showed that it occurs at higher concentrations (Ͼ128 g/ml).
In interaction studies, the antibiotics that are used clinically were tested at the following concentrations: rifampin and rifabutin, 1 mg/liter; doxycycline, ofloxacin, azithromycin, and clarithromycin, 2 mg/liter; ampicillin and vancomycin, 4 mg/ liter; and netilmicin and ceftriaxone, 8 mg/liter. Each drug was combined with each peptide at 0.5 and 1ϫ the MIC. In all tubes a logarithmic-phase inoculum of 5 ϫ 10 5 CFU/ml was added along with MH broth to give a final volume of 10 ml. All tubes were incubated overnight at 37°C and the bacterial growth in each tube was determined by preparing consecutive 1:10 (vol/vol) dilutions of a 0.1-ml aliquot of each tube in MH broth and by plating a 0.1-ml volume of each dilution onto MH agar plates. The experiments were performed in triplicate. This procedure avoided any antimicrobial carryover effect. If a combination of the peptide with other drugs caused a decrease in the viable cell count of Ն2 log 10 compared with that obtained with the most active single agent, the effect of the combination was considered a positive interaction. If the decrease in viable cell count was 1 to 2 log 10 , the effect of the combination was considered additive (8, 13) .
The susceptibilities of each strain are listed in Table 1 . The six isolates were more susceptible to nisin and ranalexin, while magainin II was less potent. Killing by nisin was shown to be the most rapid (Fig. 1a) : its activity was complete after a 20-min exposure period. Killing by ranalexin was complete after a 30-min exposure period (Fig. 1b) , while killing by magainin II was complete after a 60-min exposure (Fig. 1c ). Overall, an increase in killing at 24 h of greater than 100-fold was observed when the peptides were combined with ampicillin, ceftriaxone, rifabutin, rifampin, azithromycin, clarithromycin, VOL. 43, 1999 43, NOTES 2095 and vancomycin, while additive effects were observed with doxycycline and ofloxacin. In particular, a Ն4 log 10 decrease in viable cell counts was found when nisin and ranalexin at concentrations of 0.5 and 1ϫ the MICs were combined with azithromycin, clarithromycin, rifampin, and rifabutin. A 3-log 10 decrease in viable cell counts was found when nisin and ranalexin at concentrations of 0.5 and 1ϫ the MICs were combined with beta-lactams and vancomycin. Finally, a 3-log 10 decrease in viable cell counts was found when magainin II at a concentration of 1ϫ the MIC was combined with ampicillin, ceftriaxone, rifabutin, rifampin, azithromycin, clarithromycin, and vancomycin. Our data demonstrate that nisin and ranalexin are active against R. equi and show rapid bactericidal effects. On the contrary, magainin II demonstrated less potency. There are few data on the concentration-or time-dependent killing kinetics of bacteria by polycationic peptides; nevertheless, our observations are in agreement with those in recent reports of studies which showed that killing by peptides is very rapid and results in log orders of cell death within minutes of peptide addition (11, 14, 19) . Studies with combinations of drugs and peptides showed that each peptide exhibited a positive interaction with several antibiotics. Previous reports demonstrated that combinations of polycationic peptides, especially the polymyxin-like peptides, and lipophilic and amphiphilic agents such as rifampin, the macrolides, fusidic acid, and novobiocin have synergistic properties. Actually, polymyxin-like peptides allow maximal entry of several hydrophobic substrates inside the cell (6, 10, 16, 18) .
In conclusion, our data suggest that the polycationic peptides may be valuable as adjuvants for antimicrobial chemotherapy. Their positive in vitro interaction with agents that are used clinically also suggest that the peptides should be considered for testing in vivo for use as part of antimicrobial combination therapy.
